Retractable Technologies (RVP) risk factors, FY2024 10-K

Retractable Technologies's FY2024 10-K, filed Mar 28, 2025, lists 15 risk factors. There is no earlier 10-K to compare against, so the most company-specific risks are listed below.

Open RVP in Gloom →
Retractable Technologies' chart, financials and news, free in your browser.Open RVP in Gloom →
Risk factors listed
150 groups
Section length
3k wordsItem 1A

Retractable Technologies's biggest risks in the FY2024 10-K

  • Foreign manufacturing reliance and new tariffs heavily threaten operations and profitability.
  • Excess pandemic inventory depresses current domestic product demand.
  • High concentration of voting power rests with CEO Thomas J. Shaw.

The risks most specific to Retractable Technologies

  • We are subject to risks associated with foreign trade policy. In 2024, we used Chinese manufacturers to produce 83.9% of our products

    New tariffs and reliance on Chinese manufacturers for 83.9% of 2024 products are expected to materially harm financial results.

  • We Are Concerned that Our Stock Price is Not Correlated with Value

    The market capitalization of $20.7 million lags significantly behind stockholders equity of $87.2 million as of December 31, 2024.

  • Our Customers Have Excess Product In Inventory and We Cannot Predict When It Will Be Depleted

    Excess domestic customer inventory from vaccination purchases is depressing demand for our products with an unknown depletion timeline.

  • We Are Challenged by Uncertainties in Obtaining and Enforcing Intellectual Property Rights

    Syringes represented 68.5% of sales in 2024, making patent invalidation or circumvention a critical threat to our competitive strength.

  • We Are Vulnerable to New Technologies

    A narrow focus on retractable needle products leaves us vulnerable to superior competing technologies that could eliminate demand.

  • We Are Controlled by One Shareholder

    CEO Thomas J. Shaw controls 53.3% of the outstanding common stock, enabling him to direct operations and elect board members.

All 15 risk factors

Headings as the filing states them, in filing order.

Other

  1. 01We are subject to risks associated with foreign trade policy. In 2024, we used Chinese manufacturers to produce 83.9% of our products
  2. 02We Are Concerned that Our Stock Price is Not Correlated with Value
  3. 03Our Customers Have Excess Product In Inventory and We Cannot Predict When It Will Be Depleted
  4. 04We Are Challenged by Uncertainties in Obtaining and Enforcing Intellectual Property Rights
  5. 05We Are Vulnerable to New Technologies
  6. 06Our Competitors Have Greater Resources
  7. 07We Are Controlled by One Shareholder
  8. 08Defensive Measures to Deter Hostile Takeovers
  9. 09Supply Chain Disruptions Could Negatively Impact our Profitability
  10. 10Vaccine Hesitancy Could Impact Demand
  11. 11We Face Inherent Product Liability Risks
  12. 12Our Business May Be Affected by Changes in the Health Care Regulatory Environment
  13. 13We May Experience Losses in Our Investment Account
  14. 14Health Crises Could Have an Adverse Effect on Our Business
  15. 15Illegal Distribution and Sale by Third Parties of Counterfeit Versions of Our Products Could Have a Negative Impact

Other Retractable Technologies 10-Ks

  • FY2025 10-K risk factors
    16 risks1 new7 reworded

    Geopolitical conflict is newly identified as a threat to component and finished-goods availability and cash flows.

    Filed Mar 27, 2026

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.